Search Within

Sonia Auna Lebowitz

Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
  3. Research Letter (2)
Groups
  1. Adult Leukemia (7)
  2. Center for Hematologic Malignancies (7)
  3. Department of Medicine (7)
  4. Hematologic Malignancies, Division of (7)
  5. Hematology-Oncology Fellows (7)
  6. GME, Medicine (6)

More Groups

People
  1. Anthony Mato (7)
  2. Lindsey Roeker (7)
  3. Meghan Thompson (6)
  4. Andrew Zelenetz (4)
  5. Gail Panton (4)
  6. Victoria Falco (4)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (3)
  4. 2020 (2)
Publications
  1. Blood (5)
  2. Clinical Cancer Research (1)
  3. Leukemia (1)
  4. Oncology Nursing Forum (1)
Publishers
  1. American Society of Hematology (5)
  2. American Association for Cancer Research (1)
  3. Nature Publishing Group (1)
  4. Oncology Nursing Society (ONS) (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)-driven, time-limited approach
    Meeting Abstract

    Dorsey, C.; Falco, V.; Pena-Velasquez, C.; Lebowitz, S.; Purdom, M.; Panton, G.
    Oncology Nursing Forum (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies
    Research Letter

    Roeker, L. E.; Eyre, T. A.; Thompson, M. C.; Lamanna, N.; Coltoff, A. R.; Davids, M. S.; Baker, P. O.; Leslie, L.; Rogers, K. A.; Allan, J. N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
    Research Letter

    Roeker, L. E.; Knorr, D. A.; Thompson, M. C.; Nivar, M.; Lebowitz, S.; Peters, N.; Deonarine, I. Jr; Momotaj, S.; Sharan, S.; Chanlatte, V.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Worldwide examination of patients with CLL hospitalized for COVID-19
    Meeting Abstract

    Roeker, L. E.; Scarfo, L.; Chatzikonstantinou, T.; Abrisqueta, P.; Eyre, T. A.; Cordoba, R.; Prat, A. M.; Villacampa, G.; Leslie, L. A.; Koropsak, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Outcomes of COVID-19 in patients with CLL: A multicenter international experience
    Journal Article

    Mato, A. R.; Roeker, L. E.; Lamanna, N.; Allan, J. N.; Leslie, L.; Pagel, J. M.; Patel, K.; Osterborg, A.; Wojenski, D.; Kamdar, M.; more...
    Blood (2020)

    Fulltext@MSK | Save